Filing Flows › ELI Lilly (LLY) › R&D spending
ELI Lilly (LLY) R&D spending by quarter
ELI Lilly's R&D spending was $4.2B in Q3 2026 (third quarter 2026), +11% from Q2 2026. Over the last 7 quarters it ranged from $2.7B (Q1 2025) to $4.2B (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $4.2B | +11% | +23% |
| Q2 2026 | $3.8B | +9% | +14% |
| Q1 2026 | $3.5B | -8% | +28% |
| Q4 2025 | $3.8B | +10% | — |
| Q3 2025 | $3.5B | +4% | — |
| Q2 2025 | $3.3B | +22% | — |
| Q1 2025 | $2.7B | — | — |
Q3 2026 at a glance
ELI Lilly, Q3 2026: revenue $24.4B (+39% year over year), operating margin 34.5%, net earnings $6.5B, operating cash flow $11.4B. The chart follows the revenue to costs, profit and cash.
Questions
What is ELI Lilly's R&D spending?
ELI Lilly's R&D spending was $4.2B in Q3 2026 (third quarter 2026), +11% from Q2 2026.
How has ELI Lilly's R&D spending changed?
Over the last 7 quarters it ranged from $2.7B (Q1 2025) to $4.2B (Q3 2026).